New drug shows promise for Long-Term control of ulcerative colitis

NCT ID NCT04277546

Terminated Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of brazikumab, a drug given as a shot every 4 weeks, for people with moderate to severe ulcerative colitis. Participants had already taken part in an earlier study of brazikumab. The goal is to see if the drug remains safe over a longer period and to gather information for possible future approval.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brazikumab
What this could lead to: If successful, this could provide a long-term treatment option for people with moderate to severe ulcerative colitis.
What could go wrong: This is an early-phase, small study focused on safety, not proof of cure. The drug may not work for everyone and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Research Site

Chula Vista, California, 91911, United States
Research Site

Lancaster, California, 93534, United States
Research Site

Colorado Springs, Colorado, 80907, United States
Research Site

Lakeland, Florida, 33813, United States
Research Site

Miami, Florida, 33165, United States
Research Site

Miami Lakes, Florida, 33016, United States
Research Site

Evansville, Indiana, 47715, United States
Research Site

Beachwood, Ohio, 44122, United States
Research Site

Oklahoma City, Oklahoma, 73112, United States
Research Site

Humble, Texas, 77346, United States
Research Site

České Budějovice, 370 01, Czechia
Research Site

Ostrava, 702 00, Czechia
Research Site

Hamburg, 20251, Germany
Research Site

Kiel, 24105, Germany
Research Site

Ulm, 89081, Germany
Research Site

Haifa, 3109601, Israel
Research Site

Jerusalem, 9103102, Israel
Research Site

Milan, 20132, Italy
Research Site

Rho, 20017, Italy
Research Site

Roma, 00168, Italy
Research Site

Kasama-shi, 309-1793, Japan
Research Site

Kashiwa-shi, 277-0871, Japan
Research Site

Minatoku, 108-8642, Japan
Research Site

Krakow, 31-513, Poland
Research Site

Rzeszów, 35-302, Poland
Research Site

Sopot, 81-756, Poland
Research Site

Torun, 87-100, Poland
Research Site

Warsaw, 00-189, Poland
Research Site

Warsaw, 03-580, Poland
Research Site

San Juan, 00927, Puerto Rico
Research Site

Cape Town, 7500, South Africa
Research Site

Cape Town, 7708, South Africa
Research Site

Plumstead, 7800, South Africa
Research Site

Wŏnju, 26426, South Korea
Research Site

Taichung, 40447, Taiwan
Research Site

Taipei, 10002, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.